TABLE 3.
Plasma pharmacodynamic fAUC/MIC parameters for RWJ-416457 and linezolid
| Strain (type) | Compound | MIC (μg/ml) |
fAUC24/MICa
|
||
|---|---|---|---|---|---|
| p.o. | s.c. | i.v.b | |||
| S. aureus ATCC 13709 | RWJ-416457 | 1 | 13 | 8.3 | 8.6 |
| (MSSA) | Linezolid | 2 | 6.6 | 5.3 | 3.6 |
| S. aureus OC8525 | RWJ-416457 | 2 | 6.3 | 4.1 | 4.3 |
| (CA-MRSA) | Linezolid | 4 | 3.3 | 2.6 | 1.8 |
| S. pneumoniae ATCC | RWJ-416457 | 1 | 13 | 8.3 | 8.6 |
| 6301 (PSSP) | Linezolid | 2 | 6.6 | 5.3 | 3.6 |
a
The free-drug plasma exposure following a single 10-mg/kg dose (p.o. and s.c.) or a single 2-mg/kg dose (i.v.) was determined from the total drug plasma levels corrected for protein binding.
b
The i.v. fAUC24/MIC ratios were determined from fAUC24 values projected for a 10-mg/kg i.v. dose.